![Ocular Drug Delivery System Market Size, Industry Analysis By Technology (Topical, Iontophoresis, Ocular Insert [Erodible and Non-Erodible], Intraocular Implants [Biodegradable and Non-Biodegradable], In Situ Gel & Punctal Plugs, and Others), Formulation Type (Liposomes & Nanoparticles, Solution, Emulsion, Suspension, and Ointment) – Global, Trends, Share And Forecast 2023-2030](https://www.infinitivedataexpert.com/assets/img/infinitive-Report-Cover.png)
All updated as on -
In 2022, the market for ocular drug delivery systems was estimated to be worth USD 69.1 billion. From 2023 to 2030, the market will grow at a CAGR of 8.35%. By 2030, it is anticipated that the global market for ocular drug delivery systems will be worth USD 140.5 billion. The region with the fastest growth is predicted to be Asia Pacific.
A important organ like the eye is affected by a number of medical conditions. Such conditions can impair a person's vision in addition to their physical health. As a result, there are numerous medication delivery methods available on the market to treat these eye illnesses. The eye's effective defence mechanism has led to the market's abundance of ophthalmic medications. In fact, ointments and eye drops make up around 70% of all eye medications that are offered on the market. However, because of the tears coming from the eyes, these creams and drops easily drain from the ocular canal. As a result, pharmaceutical companies are introducing cutting-edge and new ophthalmic formulations in emerging countries. These formulations are available to consumers as ocular inserts, nanoparticles, microemulsions, iontophoresis, and liposomes.
Different conventional and novel drug delivery systems, including emulsions, ointments, aqueous gels, suspensions, liposomes, nanomicelles, implants, dendrimers, contact lenses, and nanoparticles, have been developed to remove ocular drug delivery barriers and to increase bioavailability. Additionally, the major market competitors are concentrating on creating instruments that increase the effectiveness of spatiotemporal drug administration. For instance, pSivida Corp. announced in May 2017 that the third phase trials for Durasert, which aids in the treatment of posterior unecite infection, had produced positive 12-month follow-up data.
The market requires significant investment during the early phases of the development of cutting-edge ocular medication delivery systems. Due to the collaborations and licencing agreements with various research institutes, it is predicted that the costs associated with research and development will rise at a high rate due to the growing number of new entrants. In fact, numerous pharmaceutical firms in developed economies are already investing a sizable amount in the creation of new technologies, which is fostering market expansion.
Report Coverage
Global Ocular Drug Delivery System research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Ocular Drug Delivery System report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Ocular Drug Delivery System competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Ocular Drug Delivery System market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Ocular Drug Delivery System market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Ocular Drug Delivery System market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Valeant Pharmaceuticals International, Inc., Taiwan Liposome Company, Ltd., Ocular Therapeutix, Inc., Graybug Vision Inc., EyeGate Pharma, Clearside Biomedical, Inc., Alimera Sciences, Envisia Therapeutics, Allergan, Plc, AbbVie Inc.
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. Spherical Insights has segmented the global Ocular Drug Delivery System market based on the below-mentioned segments:
Global Ocular Drug Delivery System Market, By Formulation Type
Global Ocular Drug Delivery System market, By Disease Type
Global Ocular Drug Delivery System Market, By End User
Global Ocular Drug Delivery System market, Regional Analysis
A important organ like the eye is affected by a number of medical conditions. Such conditions can impair a person's vision in addition to their physical health. As a result, there are numerous medication delivery methods available on the market to treat these eye illnesses. The eye's effective defence mechanism has led to the market's abundance of ophthalmic medications. In fact, ointments and eye drops make up around 70% of all eye medications that are offered on the market. However, because of the tears coming from the eyes, these creams and drops easily drain from the ocular canal. As a result, pharmaceutical companies are introducing cutting-edge and new ophthalmic formulations in emerging countries. These formulations are available to consumers as ocular inserts, nanoparticles, microemulsions, iontophoresis, and liposomes.
Different conventional and novel drug delivery systems, including emulsions, ointments, aqueous gels, suspensions, liposomes, nanomicelles, implants, dendrimers, contact lenses, and nanoparticles, have been developed to remove ocular drug delivery barriers and to increase bioavailability. Additionally, the major market competitors are concentrating on creating instruments that increase the effectiveness of spatiotemporal drug administration. For instance, pSivida Corp. announced in May 2017 that the third phase trials for Durasert, which aids in the treatment of posterior unecite infection, had produced positive 12-month follow-up data.
The market requires significant investment during the early phases of the development of cutting-edge ocular medication delivery systems. Due to the collaborations and licencing agreements with various research institutes, it is predicted that the costs associated with research and development will rise at a high rate due to the growing number of new entrants. In fact, numerous pharmaceutical firms in developed economies are already investing a sizable amount in the creation of new technologies, which is fostering market expansion.
Report Coverage
Global Ocular Drug Delivery System research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Ocular Drug Delivery System report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Ocular Drug Delivery System competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Ocular Drug Delivery System market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2020 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2019 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Valeant Pharmaceuticals International, Inc., Taiwan Liposome Company, Ltd., Ocular Therapeutix, Inc., Graybug Vision Inc., EyeGate Pharma, Clearside Biomedical, Inc., Alimera Sciences, Envisia Therapeutics, Allergan, Plc, AbbVie Inc. |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Ocular Drug Delivery System Market from 2021 to 2030.
- Market Forecast for Ocular Drug Delivery System Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Ocular Drug Delivery System competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Ocular Drug Delivery System
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Ocular Drug Delivery System market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Ocular Drug Delivery System market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Valeant Pharmaceuticals International, Inc., Taiwan Liposome Company, Ltd., Ocular Therapeutix, Inc., Graybug Vision Inc., EyeGate Pharma, Clearside Biomedical, Inc., Alimera Sciences, Envisia Therapeutics, Allergan, Plc, AbbVie Inc.
Primary Target Market
- Market Players of Ocular Drug Delivery System
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. Spherical Insights has segmented the global Ocular Drug Delivery System market based on the below-mentioned segments:
Global Ocular Drug Delivery System Market, By Formulation Type
- Liposomes and nanoparticles
- Emulsion
- Solution
- Suspension
- Ointment
Global Ocular Drug Delivery System market, By Disease Type
- Glaucoma
- Diabetic retinopathy
- Dry eye syndrome
- Macular degeneration
- Cataract
- Diabetic macular edema
- Others
Global Ocular Drug Delivery System Market, By End User
- Hospitals
- Ambulatory surgical centers
- Ophthalmic clinics
- Homecare settings
Global Ocular Drug Delivery System market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive ocular drug delivery system market market research and competitor analysis for your business to help you develop more profound insights into the ocular drug delivery system market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the ocular drug delivery system market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.